Compare Glenmark Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs VENUS REMEDIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA VENUS REMEDIES GLENMARK PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 13.2 6.4 206.8% View Chart
P/BV x 2.0 1.3 147.9% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 GLENMARK PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-21
VENUS REMEDIES
Mar-21
GLENMARK PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs573314 182.3%   
Low Rs19522 879.7%   
Sales per share (Unadj.) Rs387.8444.2 87.3%  
Earnings per share (Unadj.) Rs34.450.1 68.7%  
Cash flow per share (Unadj.) Rs50.178.6 63.7%  
Dividends per share (Unadj.) Rs2.500-  
Avg Dividend yield %0.70-  
Book value per share (Unadj.) Rs249.6313.2 79.7%  
Shares outstanding (eoy) m282.1712.34 2,286.6%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.00.4 261.5%   
Avg P/E ratio x11.23.4 332.4%  
P/CF ratio (eoy) x7.72.1 358.4%  
Price / Book Value ratio x1.50.5 286.5%  
Dividend payout %7.30-   
Avg Mkt Cap Rs m108,3532,075 5,221.0%   
No. of employees `000NANA-   
Total wages/salary Rs m23,437460 5,092.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m109,4395,481 1,996.6%  
Other income Rs m502196 255.8%   
Total revenues Rs m109,9415,678 1,936.4%   
Gross profit Rs m21,289772 2,757.0%  
Depreciation Rs m4,436353 1,257.4%   
Interest Rs m3,531130 2,712.3%   
Profit before tax Rs m13,825486 2,847.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,124-132 -3,121.3%   
Profit after tax Rs m9,701618 1,570.6%  
Gross profit margin %19.514.1 138.1%  
Effective tax rate %29.8-27.2 -109.6%   
Net profit margin %8.911.3 78.7%  
BALANCE SHEET DATA
Current assets Rs m73,5962,316 3,177.8%   
Current liabilities Rs m42,010974 4,311.2%   
Net working cap to sales %28.924.5 117.9%  
Current ratio x1.82.4 73.7%  
Inventory Days Days725 26.6%  
Debtors Days Days86213 40.2%  
Net fixed assets Rs m67,0933,243 2,069.1%   
Share capital Rs m282123 228.6%   
"Free" reserves Rs m70,1483,742 1,874.7%   
Net worth Rs m70,4303,865 1,822.1%   
Long term debt Rs m38,888468 8,303.9%   
Total assets Rs m140,6895,559 2,531.0%  
Interest coverage x4.94.7 103.9%   
Debt to equity ratio x0.60.1 455.7%  
Sales to assets ratio x0.81.0 78.9%   
Return on assets %9.413.5 69.9%  
Return on equity %13.816.0 86.2%  
Return on capital %15.914.2 111.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m35,7530-   
Fx outflow Rs m12,0230-   
Net fx Rs m23,7290-   
CASH FLOW
From Operations Rs m11,3121,326 853.0%  
From Investments Rs m-6,752557 -1,211.9%  
From Financial Activity Rs m-4,418-1,622 272.3%  
Net Cashflow Rs m278269 103.3%  

Share Holding

Indian Promoters % 46.7 40.8 114.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 35.0 0.3 12,485.7%  
FIIs % 25.9 0.3 9,260.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.4 59.2 90.1%  
Shareholders   329,870 18,231 1,809.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Sensex Tanks 554 Points, Nifty Ends Near 18,100; Maruti, Tech Mahindra & Tata Consumer Plunge 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

VENUS REMEDIES 2020-21 Annual Report Analysis (Annual Result Update)

Nov 2, 2021 | Updated on Nov 2, 2021

Here's an analysis of the annual report of VENUS REMEDIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

India's Best Semiconductor Stocks(Views On News)

Jan 7, 2022

Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Looking for Consistent Compounding Stocks? Here's a Watchlist for You(Views On News)

Jan 6, 2022

These companies have generated mind boggling returns for investors over the years.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jan 18, 2022 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS